S 2740 · 116th Congress 2019–2021, ended

Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019

Latest action · Dec 14, 2019 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedOct 30, 2019
  2. Passed SenateDec 10, 2019
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019

This bill makes significant changes to the regulation by the Food and Drug Administration (FDA) of nonprescription (i.e., over-the-counter or OTC) drugs.

The bill establishes a new approval process for OTC medications. Specifically, it creates an FDA administrative order process for the evaluation of OTC products, replacing the present notice and comment rulemaking approach. Under the new process, the FDA may issue an administrative order determining that a specific OTC drug, class of drugs, or combination is generally regarded as safe and effective and not subject to the new drug application process. The FDA may also use the administrative order process to (1) determine that a drug, class of drugs, or combination poses an imminent hazard to the public health; or (2) require labeling changes to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug.

The bill provides for market exclusivity under certain circumstances. For drugs determined to be generally regarded as safe and effective pursuant to an administrative order requested by a sponsor (rather than initiated by the FDA), the requestor is granted 18 months of market exclusivity. This market exclusivity applies to an OTC drug with a new active ingredient or if the requestor conducted new human studies to get approval.

The bill allows a sponsor of a nonprescription sunscreen active ingredient or a combination of such ingredients that was subject to a proposed sunscreen order to transition to the administrative order process. Market exclusivity provisions also apply to new sunscreen active ingredients.

The FDA must establish a user fee program for OTC drugs.

Recorded votes 1

Newest first. Open one to see how every member voted.

Roll callQuestionResultDate
Senate 389On Passage of the Bill S. 2740Bill Passed91–2Dec 10, 2019

Yea 91

Nay 2

Cosponsors 5

Members who signed on, in the order they did. Signatures ran from Oct 30, 2019 to Dec 10, 2019; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-PARobert P. Casey Jr.OriginalOct 30, 2019
R-INMike BraunOct 31, 2019
R-TNLamar AlexanderNov 7, 2019
D-WAPatty MurrayNov 7, 2019
I-AZKyrsten SinemaDec 10, 2019

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Oct 30, 2019Markup Oct 31, 2019Reported Nov 5, 2019
HouseEnergy and Commerce Committee
Referred Dec 12, 2019
Health Subcommittee
Referred Dec 14, 2019

Actions 10

Everything that happened, newest first.

  1. Dec 14, 2019Referred to the Subcommittee on Health.
  2. Dec 11, 2019Message on Senate action sent to the House.
  3. Dec 11, 2019Received in the House.
  4. Dec 11, 2019Referred to the House Committee on Energy and Commerce.
  5. Dec 10, 2019Passed/agreed to in Senate: Passed Senate without amendment by Yea-Nay Vote. 91 - 2. Record Vote Number: 389. (consideration: CR S6921-6930; text: CR S6921-6930)

In the Congressional Record 2

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S6915, S6918, S6921, S6944, S6945Text printed S6921–S6930Recorded votes S6921enactJohnny Isakson R-GA, Lamar Alexander R-TN, Patty Murray D-WA, Richard Burr R-NC, Robert P. Casey Jr. D-PADec 10, 2019
SenateDebate and remarks S6900Thom Tillis R-NCDec 9, 2019

Related bills 4

Companion bills and other measures the record links to this one.

Titles 9

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes.
Short Title(s) as Introduced
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Short Title(s) as Reported to Senate
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Short Title(s) as Passed Senate
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Short Title(s) as Introduced for portions of this bill
Over-the-Counter Monograph User Fee Act of 2019
Short Title(s) as Reported to Senate for portions of this bill
Over-the-Counter Monograph User Fee Act of 2019
Short Title(s) as Passed Senate for portions of this bill
Over-the-Counter Monograph User Fee Act of 2019
Short Titles from RFH (Referred to House) bill text
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Short Titles from RFH (Referred to House) for portions of this bill text
Over-the-Counter Monograph User Fee Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 4

Each version as it was printed, newest first.

  1. Dec 11, 2019Referred in House
  2. Dec 10, 2019Engrossed in Senate
  3. Nov 5, 2019Reported to Senate
  4. Oct 30, 2019Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.